Therapy areas
We are focusing our efforts on preventing and curing cancer by developing individualized NK cell therapies. We strongly believe that our technology platform and leading investigational drug candidate, CellProtect, has the ideal properties for being a critical component in tomorrow’s cancer prevention strategies and treatments.
Multiple myeloma
Multiple myeloma (MM), our leading target for CellProtect, with over 100 000 new cases per year, is the 3rd most frequent haematological malignancy worldwide, after leukemia and non-Hodgkin lymphoma. Multiple myeloma treatment has improved remarkably over the last 2 decades with the development and introduction of numerous novel agents leading to more effective treatments, including 3 generations of immunomodulator agents (thalidomide, lenalidomide, and pomalidomide), 2 generations of proteasome inhibitors (bortezomib, then carfilzomib and ixazomib) and most recently, the CD38 antibodies (daratumumab and isatuximab). These novel agents significantly improved the overall survival of patients with multiple myeloma. Regardless, multiple myeloma remains a fatal disease in the majority of cases. Therapies still need improvement through the definition of new therapeutic strategies with this new armamentarium and development of new drugs.
Smouldering Multiple Myeloma
Smouldering Multiple Myeloma (SMM) is a pre-stage to Multiple Myeloma. It is distinguished from multiple myeloma based on the lack of end-organ damage. Since SMM is asymptomatic, newly diagnosed patients are typically diagnosed as part of the work up for diagnosing other disorders. Therefor there no complete picture of the disease exists. A prospective observational registry designed to document real-world treatment and outcomes in newly diagnosed MM patients in Sweden using the Swedish Myeloma Registry, 14% of the patients were classified as having SMM.